The Australian biotech firm, CSL Ltd, has revealed a sizeable increase in its net profit after tax, reaching $1.90bn, for the half-year concluding on December 31, 2023. This indicates a 20% surge on a constant currency basis. The per-share net income has also seen a rise from $3.36 in the previous year, coming in at $3.92.
The company's underlying profit was equally encouraging, standing at $2.02bn, marking a 13% uptick on a constant currency basis. Furthermore, revenues have taken a significant leap, settling at $8.05bn, which is an 11% increase on a constant currency basis.
Looking at their outlook for the coming fiscal year of 2024, CSL reiterated its confidence, expecting an underlying profit and net profit after tax ranging between $2.9bn and $3.0bn. This would denote approximately 13%-17% growth on the fiscal year 2023's figures.
In anticipation of delivering double-digit earnings growth annually over the medium term, CSL asserts it is strongly positioned. Keeping its stakeholders in mind, CSL has announced an interim ordinary dividend of $1.19 per share, scheduled to be paid on April 3, 2024, for the first half of the year 2024, calculated based on shares in issue at the reporting date.
